Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires $25,180.16 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 4,918 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were purchased at an average cost of $5.12 per share, for a total transaction of $25,180.16. Following the acquisition, the chief executive officer directly owned 3,180,394 shares in the company, valued at $16,283,617.28. This represents a 0.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

KindlyMD Price Performance

Shares of NASDAQ NAKA traded up $0.24 during trading hours on Thursday, reaching $6.30. The stock had a trading volume of 306,929 shares, compared to its average volume of 197,571. The company has a market cap of $112.77 million, a price-to-earnings ratio of -0.18 and a beta of 15.95. KindlyMD, Inc. has a twelve month low of $3.33 and a twelve month high of $432.40. The business’s fifty day moving average is $4.45 and its two-hundred day moving average is $7.29.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. The business had revenue of $35.87 million for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. Sell-side analysts forecast that KindlyMD, Inc. will post -16.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NAKA has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. TD Cowen increased their price target on shares of KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, KindlyMD presently has a consensus rating of “Hold” and an average price target of $22.33.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Alyeska Investment Group L.P. acquired a new stake in shares of KindlyMD in the 4th quarter valued at $8,993,000. ParaFi Capital LP acquired a new stake in shares of KindlyMD during the 3rd quarter worth about $443,055,000. Hunting Hill Global Capital LLC bought a new position in KindlyMD during the 4th quarter valued at about $4,672,000. Yorkville Advisors Global LP bought a new position in KindlyMD during the 4th quarter valued at about $3,265,000. Finally, UBS Group AG acquired a new position in KindlyMD in the fourth quarter valued at about $2,958,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.